MedTrace Logo

Bladder Cancer and Neoadjuvant Chemotherapy Efficiency Before Cystectomy

NCT06294054 · Status: ACTIVE_NOT_RECRUITING · Type: OBSERVATIONAL · Enrollment: 707

Last updated 2024-03-06

No results posted yet for this study

Summary

This study will allow the investigators to better assess the efficiency of neoadjuvant chemotherapy before cystectomy by training a predictive model on different patient cohorts with bladder cancer.

Conditions

Interventions

COMBINATION_PRODUCT

neoadjuvant chemotherapy with cisplatine

Blood from patient having muscle invasive bladder cancer who benefit from neoadjuvant chemotherapy with cisplatine

Sponsors & Collaborators

  • Institut Curie

    collaborator OTHER

  • University Hospital, Rouen

    lead OTHER

Principal Investigators

  • Yves ALLORY, MD · Institut Curie

Eligibility

Min Age
18 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-04-01
Primary Completion
2026-03-31
Completion
2026-03-31

Countries

  • France

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06294054 on ClinicalTrials.gov